family with sequence similarity 186 member AGenealiases: []
Q-omics provides the consensus-scored FAM186A profile across patient tissues and cancer cell-line models. FAM186A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAM186A is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, FAM186A RNA expression shows 17,067 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where FAM186A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM186A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM186A survival associations across molecular data types. FAM186A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM186A RNA expression–survival associations across cancer types. High FAM186A expression shows unfavorable associations in KIRC, COAD and LIHC, but favorable associations in PAAD, UCS and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAM186A RNA expression.
This table summarizes FAM186A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM186A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM186A shows lower tumor expression in KICH and higher tumor expression in KIRC, LIHC, STAD, CHOL and PRAD. The KIRC box plot shows higher FAM186A RNA expression in tumor versus normal tissue (log2 FC = +0.090, t-test p < 0.001).
This table shows molecular features associated with FAM186A in patient tissues and cancer cell lines. In patient samples, FAM186A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM186A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and UPPER_AERODIGESTIVE_TRACT.
